Abstract
The ability of histone deacetylase inhibitors to modulate the expression of genes relevant for growth or apoptotis regulation supports their interest in combination treatments of resistant tumors. We explored the effect of the combination of the histone deacetylase inhibitor ST2782 and the proteasome inhibitor bortezomib in ovarian carcinoma cell lines, including the IGROV-1 cell line and two p53 mutant platinum-resistant sublines (IGROV-1/OHP and IGROV-1/Pt1). We found a synergistic interaction between the two drugs, more evident in the p53-mutant resistant sublines, which was associated with increa sed apoptosis. The treatment with ST2782 resulted in early induction of Bax as well as in cleavage of caspase 3 and poly (ADP-ribose) polymerase only in the resistant cell lines. The inhibition of p53-transcriptional transactivation by pifithrin alpha in IGROV-1 cells enhanced the synergism. Conversely, knockdown of endogenous wild-type p53 in IGROV-1 cells determined synergism reduction. These opposite effects support the relevance of the transactivation-deficient mutant p53 as a synergism determinant. Moreover, in vivo studies indicated that tumor growth inhibition tended to be more evident in mice receiving the drug combination than in those treated with bortezomib alone. Overall, our study supports the potential effectiveness of the combination in platinum drug-resistant ovarian cancer carrying mutant p53.
Copyright © 2012 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Antineoplastic Agents / pharmacology*
-
Antineoplastic Agents / therapeutic use
-
Antineoplastic Combined Chemotherapy Protocols / pharmacology*
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Apoptosis / drug effects
-
Benzothiazoles / pharmacology
-
Boronic Acids / pharmacology*
-
Boronic Acids / therapeutic use
-
Bortezomib
-
Carcinoma / drug therapy
-
Carcinoma / genetics
-
Carcinoma / pathology
-
Caspase 3 / genetics
-
Caspase Inhibitors
-
Cell Line, Tumor
-
Cisplatin / pharmacology
-
Drug Resistance, Neoplasm
-
Drug Synergism
-
Female
-
Gene Expression Regulation, Neoplastic
-
Histone Deacetylase Inhibitors / pharmacology*
-
Histone Deacetylase Inhibitors / therapeutic use
-
Histone Deacetylases / genetics
-
Histone Deacetylases / metabolism
-
Humans
-
Neoplasm Proteins / genetics
-
Neoplasm Proteins / metabolism*
-
Ovarian Neoplasms / drug therapy
-
Ovarian Neoplasms / genetics
-
Ovarian Neoplasms / pathology
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Poly(ADP-ribose) Polymerases / genetics
-
Protease Inhibitors / pharmacology*
-
Protease Inhibitors / therapeutic use
-
Proteasome Endopeptidase Complex / metabolism
-
Proteasome Inhibitors
-
Pyrazines / pharmacology*
-
Pyrazines / therapeutic use
-
Toluene / analogs & derivatives
-
Toluene / pharmacology
-
Tumor Suppressor Protein p53 / antagonists & inhibitors
-
Tumor Suppressor Protein p53 / deficiency
-
Tumor Suppressor Protein p53 / genetics
-
bcl-2-Associated X Protein / agonists
-
bcl-2-Associated X Protein / genetics
Substances
-
Antineoplastic Agents
-
Benzothiazoles
-
Boronic Acids
-
Caspase Inhibitors
-
Histone Deacetylase Inhibitors
-
Neoplasm Proteins
-
Poly(ADP-ribose) Polymerase Inhibitors
-
Protease Inhibitors
-
Proteasome Inhibitors
-
Pyrazines
-
Tumor Suppressor Protein p53
-
bcl-2-Associated X Protein
-
Toluene
-
Bortezomib
-
pifithrin
-
Poly(ADP-ribose) Polymerases
-
Caspase 3
-
Proteasome Endopeptidase Complex
-
Histone Deacetylases
-
Cisplatin